166 related articles for article (PubMed ID: 785107)
1. Regional immunotherapy with intrapleural BCG for lung cancer.
McKneally MF; Maver C; Kausel HW; Alley RD
J Thorac Cardiovasc Surg; 1976 Sep; 72(3):333-8. PubMed ID: 785107
[TBL] [Abstract][Full Text] [Related]
2. Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer.
McKneally MF; Maver C; Lininger L; Kausel HW; McIlduff JB; Older TM; Foster ED; Alley RD
J Thorac Cardiovasc Surg; 1981 Apr; 81(4):485-92. PubMed ID: 7009993
[TBL] [Abstract][Full Text] [Related]
3. Intralesional BCG immunotherapy of pulmonary tumors.
Holmes EC; Ramming KP; Bein ME; Coulson WF; Callery CD
J Thorac Cardiovasc Surg; 1979 Mar; 77(3):362-8. PubMed ID: 762979
[TBL] [Abstract][Full Text] [Related]
4. Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. Preliminary report of the National Cancer Institute Lung Cancer Study Group.
J Thorac Cardiovasc Surg; 1981 Nov; 82(5):649-57. PubMed ID: 7029149
[TBL] [Abstract][Full Text] [Related]
5. Modified stage I (T1N0M0, T2N0M0), nonsmall cell lung cancer: treatment results, recurrence patterns, and adjuvant immunotherapy.
Little AG; DeMeester TR; Ferguson MK; Skinner DB; Hoffman PC; Skosey C; Blough RR; Golomb HM
Surgery; 1986 Oct; 100(4):621-8. PubMed ID: 3020725
[TBL] [Abstract][Full Text] [Related]
6. Complications of intrapleural BCG in the treatment of operable non-small-cell bronchial carcinoma.
Law MR; Lam WK; Studdy PR; Pugsley WB; Hodson ME
Br J Dis Chest; 1982 Apr; 76(2):151-6. PubMed ID: 7093133
[TBL] [Abstract][Full Text] [Related]
7. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.
Winters WD; Lamm DL
Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
[TBL] [Abstract][Full Text] [Related]
9. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
10. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
Saint F
Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
12. Preliminary results of combined surgery and adjuvant Bacillus Calmette-Guérin plus levamisole treatment of resectable lung cancer.
Wright PW; Hill LD; Peterson AV; Pinkham R; Johnson L; Ivey T; Bernstein I; Bagley C; Anderson R
Cancer Treat Rep; 1978 Nov; 62(11):1671-5. PubMed ID: 215304
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of intrapleural Bacillus Calmette-Guérin treatment in animals.
Filardi MJ; Codish SD; Civerchia L; Howard RK; McKneally MF
Cancer Res; 1979 Sep; 39(9):3673-6. PubMed ID: 383285
[TBL] [Abstract][Full Text] [Related]
14. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
15. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
[TBL] [Abstract][Full Text] [Related]
17. Active specific immunotherapy with an autologous tumor cell vaccine in patients with resected non-small cell lung cancer.
Schulof RS; Mai D; Nelson MA; Paxton HM; Cox JW; Turner ML; Mills M; Hix WR; Nochomovitz LE; Peters LC
Mol Biother; 1988; 1(1):30-6. PubMed ID: 2855788
[TBL] [Abstract][Full Text] [Related]
18. Survival of lung cancer patients treated with BCG and/or a soluble BCG fraction (F70) after surgery, radiotherapy and chemotherapy.
Hadźiev S; Kavaklieva-Dimitrova J; Mandulova P; Madźarova S; Spassova M
Neoplasma; 1980; 27(1):83-94. PubMed ID: 7374861
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.
Lamm DL
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S86-90. PubMed ID: 11010830
[TBL] [Abstract][Full Text] [Related]
20. [Clinical trials of immunotherapy in lung cancer].
Budzyński W; Orłowski TM
Wiad Lek; 1984 Jul; 37(13):997-1003. PubMed ID: 6393588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
